| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000039671 |
| Receipt No. | R000045187 |
| Scientific Title | A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions |
| Date of disclosure of the study information | 2021/12/31 |
| Last modified on | 2022/07/07 (Ver. 9) |
| Basic information | ||
| Public title | A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions | |
| Acronym | A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions | |
| Scientific Title | A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions | |
| Scientific Title:Acronym | A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adult | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the effect on cognitive function of ONO-SR/AST-SOYPC daily intake, for 12 weeks |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Tests for cognitive functions |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of test food daily intake, for 12 weeks | |
| Interventions/Control_2 | Intake of placebo daily intake, for 12 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Healthy males and females from 60 to 85 years of age
(2) Subjects with self-awareness of forgetfulness or Those who are pointed out that there is forgetfulness |
|||
| Key exclusion criteria | (1) Subjects who constantly use health food richly containing involvement ingredient
(2) Subjects who regularly take drugs or health foods which may affect this study more than once a week (3) Subjects whose visual acuity is too low to perform test (4) Subjects whose hearing acuity is too low to perform test (5) Subjects having a disease of mental disorder, dementia, cranial nerve disease, or cerebrovascular disease. (6) Subjects with current menopausal disorders (7) Subjects taking drugs that may affect the results of the study (8) Subjects having a disease requiring treatment or a history of serious diseases for which medication was required (9) Subjects having a drug dependence, alcohol dependence requiring treatment or a history of serious alcohol dependence (10) Subjects suspected of having dementia based on cognitive function tests and physician interviews. (11) Subjects who may experience irregularities in their lives more than once during the study period due to night shifts, etc. (12) Subjects who are current smokers or have started smoking cessation within 12 months before the pre-treatment test. (13) Subjects who have performed the cognitive tests within 12 months prior to the pre-treatment test. (14) Subjects who donated or transfused 200 mL or 400 mL of whole blood within 3 months before the pre-treatment test. (15) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study. (16) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on the pre-treatment test. (17) Subjects at risk of developing allergy in relation to the study. (18) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire (19) Subjects judged as unsuitable for the study by the investigator for other reasons. |
|||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | ONO PHARMACEUTICAL CO., LTD. | ||||||
| Division name | Business Design Department | ||||||
| Zip code | 541-8564 | ||||||
| Address | 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka | ||||||
| TEL | 06-6263-2924 | ||||||
| ya.noda@ono.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | TTC Co., Ltd. | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 150-0021 | ||||||
| Address | Seibu Shinkin Bank Ebisu Bldg., 1-20-2, Ebisunishi, Shibuya-ku, Tokyo | ||||||
| TEL | 03-5459-5329 | ||||||
| Homepage URL | |||||||
| t.nakagawa@ttc-tokyo.co.jp | |||||||
| Sponsor | |
| Institute | TTC Co., Ltd |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ono Pharmaceutical co.,ltd |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Medical Station Clinic Research Ethics Committee |
| Address | 3-12-8, Takaban, Meguroku, Tokyo |
| Tel | 03-6452-2712 |
| t.saito@ttc-smo.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 100 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045187 |